NetworkNewsBreaks – Atreca Inc. (NASDAQ: BCEL) Closes Public Offering Estimated at $125M
Atreca (NASDAQ: BCEL) announced it has closed its underwritten public offering of 7,031,250 shares of Class A Common Stock and 781,250 shares of Class B Common Stock. The biopharmaceutical company, which utilizes a differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, sold shares at the public offering price of $16 per share. The public offering resulted in gross proceeds for Atreca of an estimated $125 million. Atreca also granted the underwriters a 30-day option to purchase up to 1,171,875 additional shares of its Class A Common Stock at the public offering…







